Weekly Digest – December 2025 Weekly Digest – December 2025 09 December 2025: DESTINY-Ovarian01 Phase 3 Trial of ENHERTU initiated as first-line maintenance therapy in patients with HER2 expressing advanced ovarian cancer The DESTINY-Ovarian01 Phase 3 trial has reached a […]
Weekly Digest – December 2025 Weekly Digest – December 2025 11 December 2025: Biohaven presents clinical safety and efficacy data for BHV-1510, a next-generation Trop2 ADC in combination with cemiplimab at the 2025 ESMO Immuno-Oncology Congress Biohaven reported new clinical […]
Weekly Digest – December 2025 Weekly Digest – December 2025 05 December 2025: Korea BNC and ProAbtek jointly develop Albubody’s dual-target next-generation ADC anticancer drug Korea BNC and ProAbTech signed a joint R&D deal to develop dual-target ADCs powered by […]
Weekly Digest – December 2025 Weekly Digest – December 2025 10 December 2025: Oxford BioTherapeutics enters into a strategic collaboration with GSK to discover novel targets for antibody-based therapeutics for the treatment of cancer Oxford BioTherapeutics (OBT) and GSK have […]
Weekly Digest – December 2025 Weekly Digest – December 2025 02 December 2025: MHRA approves Tisotumab vedotin for the treatment of cervical cancer The MHRA has approved Tisotumab vedotin (Tivdak) for adults with recurrent or metastatic cervical cancer whose disease […]
Weekly Digest – December 2025 Weekly Digest – December 2025 01 December 2025: European Medicines Agency validates Type II Variation Application for PADCEV (Enfortumab vedotin) with KEYTRUDA (Pembrolizumab) for certain patients with muscle-invasive bladder cancer The EMA has validated Astellas’ […]
Weekly Digest – December 2025 Weekly Digest – December 2025 04 December 2025: Celltrion’s ADC anticancer drug ‘CT-P70’ receives Fast Track Designation from the US FDA Celltrion’s ADC candidate CT-P70 has received FDA Fast Track Designation for metastatic non-squamous NSCLC […]
Weekly Digest – December 2025 Weekly Digest – December 2025 01 December 2025: IDEAYA Biosciences announces IND clearance for IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC targeting multiple solid tumor types IDEAYA has received FDA IND clearance for IDE034, […]
Weekly Digest – December 2025 Weekly Digest – December 2025 04 December 2025: Kelun-Biotech and Crescent Biopharma announce strategic partnership to develop and commercialize novel oncology therapeutics Kelun-Biotech and Crescent Biopharma have entered a strategic partnership to co-develop and commercialize […]
Weekly Digest – December 2025 Weekly Digest – December 2025 03 December 2025: SK Biopharm secures European actinium‑225 supply from Germany’s Eckert & Ziegler SK Biopharm has signed an agreement with Germany’s Eckert & Ziegler to secure a reliable supply […]
